首页> 外文期刊>Urology >Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy.
【24h】

Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy.

机译:根治性前列腺切除术后放疗的前列腺局部复发癌。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVES: To evaluate the outcome of patients treated with irradiation (RT) for isolated, clinically apparent local tumor recurrence following prostatectomy for carcinoma of the prostate (CaP). METHODS: Between May 1979 and July 1992, 35 patients received external-beam RT as sole salvage therapy for post-prostatectomy locally recurrent CaP. Patient outcome was evaluated through retrospective medical record review with respect to clinical and prostate-specific antigen-based (that is, biochemical) control rates, as well as disease-free (clinical and biochemical) and overall survival estimates. Chronic RT-induced morbidity was also examined, and pre-RT disease characteristics were evaluated for their association with disease outcome. RESULTS: With median follow-up of 5.2 years (range 1.7 to 12.1) in survivors (30 patients), 19 patients (54%) had clinical (local, 1 patient [3%]; metastatic, 7 patients [20%]) or biochemical only (11 patients [31%]) relapse. The 8-year clinical relapse-free and any relapse-free (clinical or biochemical) rates were 80% and 56%, respectively, whereas the overall survival estimate was 97%. A chronic complication(s) of treatment was noted in 15 patients (43%) but spontaneously resolved in all but 6 (17%); persistent complications were mild and associated with rectal (grade 1 to 2, 14%) and lymphatic (3%) systems. The interval between prostatectomy and local tumor recurrence, the pre-RT prostate-specific antigen serum level, the pathologic stage, and tumor differentiation may be associated with disease outcome. CONCLUSIONS: External-beam RT resulted in excellent local tumor control without serious long-term morbidity in most patients. Although this study could not define an optimal management strategy (for example, symptomatic measures only, RT, or hormonal therapy), these results provided outcome measures, in relationship to pre-RT tumor-related factors, that may be valuable for clinical decision-making.
机译:目的:评估接受前列腺癌(CaP)前列腺切除术后接受放射治疗(RT)的孤立,临床上明显的局部肿瘤复发患者的结局。方法:1979年5月至1992年7月,有35例患者接受了体外束RT作为前列腺癌术后局部复发性CaP的唯一挽救疗法。通过回顾性医疗记录审查对患者的结局进行评估,包括基于临床和前列腺特异性抗原(即生化)的控制率,无病(临床和生化)和总体生存率的估计。还检查了慢性RT诱发的发病率,并评估了RT前疾病特征与疾病结局的关系。结果:幸存者(30例)中位随访时间为5.2年(范围为1.7至12.1),其中19例(54%)有临床表现(局部,1例[3%];转移性,7例[20%])或仅生化(11例[31%])复发。 8年临床无复发和任何无复发(临床或生化)率分别为80%和56%,而总生存率估计为97%。有15例患者(43%)出现慢性并发症,但除6例(17%)以外的所有患者均自发消退。持续性并发症为轻度并与直肠(1至2级,14%)和淋巴系统(3%)相关。前列腺切除术和局部肿瘤复发之间的时间间隔,RT前前列腺特异性抗原血清水平,病理分期和肿瘤分化可能与疾病结局有关。结论:大多数患者在体外束RT可以很好地控制局部肿瘤,而没有严重的长期发病。尽管这项研究无法确定最佳的治疗策略(例如,仅对症措施,RT或激素疗法),但这些结果提供了与RT前肿瘤相关因素相关的结局指标,可能对临床决策具有重要意义-制造。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号